- Home
- MARPS vs CVKD Comparison
MARPS vs CVKD Comparison
Compare MARPS & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MARPS
- CVKD
- Stock Information
- Founded
- MARPS 1956
- CVKD 2022
- Country
- MARPS United States
- CVKD United States
- Employees
- MARPS N/A
- CVKD N/A
- Industry
- MARPS Oil & Gas Production
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- MARPS Energy
- CVKD Health Care
- Exchange
- MARPS Nasdaq
- CVKD Nasdaq
- Market Cap
- MARPS 7.9M
- CVKD 17.1M
- IPO Year
- MARPS N/A
- CVKD 2023
- Fundamental
- Price
- MARPS $4.10
- CVKD $14.45
- Analyst Decision
- MARPS
- CVKD Strong Buy
- Analyst Count
- MARPS 0
- CVKD 2
- Target Price
- MARPS N/A
- CVKD $52.50
- AVG Volume (30 Days)
- MARPS 29.2K
- CVKD 59.6K
- Earning Date
- MARPS 01-01-0001
- CVKD 11-08-2024
- Dividend Yield
- MARPS 8.19%
- CVKD N/A
- EPS Growth
- MARPS N/A
- CVKD N/A
- EPS
- MARPS 0.36
- CVKD N/A
- Revenue
- MARPS $1,044,997.00
- CVKD N/A
- Revenue This Year
- MARPS N/A
- CVKD N/A
- Revenue Next Year
- MARPS N/A
- CVKD N/A
- P/E Ratio
- MARPS $11.36
- CVKD N/A
- Revenue Growth
- MARPS N/A
- CVKD N/A
- 52 Week Low
- MARPS $3.77
- CVKD $5.40
- 52 Week High
- MARPS $6.50
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- MARPS 49.68
- CVKD 56.80
- Support Level
- MARPS $3.98
- CVKD $11.19
- Resistance Level
- MARPS $4.19
- CVKD $17.95
- Average True Range (ATR)
- MARPS 0.20
- CVKD 1.37
- MACD
- MARPS -0.02
- CVKD 0.10
- Stochastic Oscillator
- MARPS 14.63
- CVKD 49.64
About MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.